EP1853233A1 - Preparation with anti-microbial action for external use - Google Patents

Preparation with anti-microbial action for external use

Info

Publication number
EP1853233A1
EP1853233A1 EP05715663A EP05715663A EP1853233A1 EP 1853233 A1 EP1853233 A1 EP 1853233A1 EP 05715663 A EP05715663 A EP 05715663A EP 05715663 A EP05715663 A EP 05715663A EP 1853233 A1 EP1853233 A1 EP 1853233A1
Authority
EP
European Patent Office
Prior art keywords
preparation
silver
precursor
preparation according
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05715663A
Other languages
German (de)
French (fr)
Inventor
Christoph Cichos
J. Peter Guggenbichler
Irmgard Cichos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1853233A1 publication Critical patent/EP1853233A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Definitions

  • the invention relates to an antimicrobial preparation for external use for pharmaceutical and / or cosmetic purposes
  • EP 0732 773 A1 discloses an antibacterial toothpaste which contains a calcium-containing phosphate which carries an antibacterial metal in the metallic state.
  • antibacterial metal silver, copper, zinc is proposed.
  • the metallic state of the metal is achieved by treating the phosphate with an appropriate aqueous metal salt solution and then reducing the metal salt on the phosphate in a thermal conversion step at at least 800 ° C.
  • the method provides no reproducible results in terms of antibacterial efficacy of the resulting toothpaste due to the difficult to quantify distribution and concentration of the antibacterial metal on the phosphate as well as with respect to the obtained granulation of phosphate and metal. In addition, it must be expected in the thermal process with losses of metal.
  • EP 0251 783 B1 / DE 37 85 253 T2 discloses an antimicrobial composition
  • Silver compounds have the disadvantage that ionic silver is unstable in the presence of light or other radiation. Also, this property of the silver compounds can not be absolutely suppressed by depositing the deposited silver compound only on certain carriers which are substantially insoluble in an aqueous environment. Therefore, such compositions generally have inadequate shelf life and thus only limited antimicrobial efficacy. However, this period of time is difficult to quantify, so that the user of such a product is unsure about the extent to which the same is still sufficiently active.
  • nanoscale silver by means of a prepared precursor in plastic products, such as catheters, tubes, etc., which are used for medical purposes, introduced.
  • the invention is based on the object of developing an antimicrobially active preparation for substantially human external application for pharmaceutical and / or cosmetic purposes, which contains nanoscale metallic silver which can be quantified with high reproducibility and which has a stable storage stability.
  • the object is achieved by an antimicrobial active preparation using nanoscale elemental silver, which is deposited on an inert carrier material and the coated carrier material is incorporated in the form of an intermediate in the preparation, wherein the preparation is characterized in that it is a substantially pasty Having consistency and the precursor of feinstteiligem barium sulfate and / or equivalent inert and medically acceptable inorganic compounds and / or microcellulose on which the nanoscale silver is deposited, is prepared.
  • the silver-containing precursor contains silver in an amount of 0.1 to 50% by mass, especially 3 to 10% by mass, and is contained in an amount of 0.2 to 8% by mass in the antimicrobial preparation.
  • the precursor can be added in the original preparation of an antimicrobial preparation according to the invention. However, the precursor can also be introduced at any time and simply subsequently in a neutral or for pharmaceutical and / or cosmetic purposes already suitable or already with otherwise effective ingredients added pasty preparation to obtain an inventive antimicrobial preparation. It may also prove advantageous in some cases to activate the precursor by adding water-soluble and / or insoluble silver salts in order to further increase the oligodynamic effect of the nanoscale silver.
  • the antimicrobial efficacy of the preparation must be set precisely and easily reproducible thanks to the good miscibility of all components.
  • the antimicrobial pasty preparation according to the invention is widely used in the form of ointments, creams, gels, toothpastes etc. for pharmaceutical and cosmetic and human medical purposes and brings surprisingly fast decay and healing effects in dermatoses, such as acne vulgaris, eczema, eczema, burns, Herpes, fungal attack, fissures, in the prevention and treatment of wound infections, periodontitis, etc., and it is easily and successfully used in the ENT, anal and genital area.
  • the analogous application of the antimicrobial preparation of the invention in veterinary medicine is provided.
  • a simple commercial toothpaste was made with a precursor in the form of a

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a preparation with an anti-microbial action for external use and pharmaceutical and/or cosmetic purposes, said preparation using nanoscalar silver that has been deposited on an inert support material, the coated support material being integrated into the preparation in the form of an intermediate product. Said preparation is characterised by a pasty consistency and by a contained intermediate product consisting of a fine-particled barium sulphate, or similar inert, medically safe inorganic compounds and/or micro-cellulose, onto which the nanoscalar elemental silver is deposited. The intermediate product preferably contains 0.1 to 50 mass % silver and the preparation contains 0.2 to 80 mass % intermediate product. The preparation can be used in a wide range of applications for reducing the symptoms of and therapeutically treating microbial infections of the skin, ENT regions and the anal and genital area and can also be used preventively.

Description

Antimikrobiell wirkendes Präparat zur äußerlichen AnwendungAntimicrobial preparation for external use
Die Erfindung betrifft ein antimikrobiell wirkendes Präparat zur äußerlichen Anwendung für pharmazeutische und/oder kosmetische ZweckeThe invention relates to an antimicrobial preparation for external use for pharmaceutical and / or cosmetic purposes
Aus DE 199 19 770 Al ist bekannt, nanoskalige antimikrobielle Wirkstoffe zur Herstellung von Zahnpasten oder Zahnputzgelen zu verwenden. Vorgeschlagen wird ein breites Spektrum nichtbasischer sowie schwer wasserlöslicher pharmakologisch aktiver aliphatischer und/oder aromatischer Verbindungen. Die massenhafte Vielfalt der angebotenen organischen Wirkstoffe macht es dem Anwender der Präparate jedoch schwer, seine individuelle Spezifik der Verträglichkeit einzuordnen, um eine möglicherweise bestehende Sensibilität gegenüber bestimmten Organika zu berücksichtigen. Das kann letztlich dazu führen, dass er auf die Anwendung derartiger, ihm kritisch erscheinender Produkte lieber verzichtet.From DE 199 19 770 Al it is known to use nanoscale antimicrobial agents for the production of toothpastes or toothbrush gels. A broad spectrum of non-basic and poorly water-soluble pharmacologically active aliphatic and / or aromatic compounds is proposed. However, the mass diversity of the organic active ingredients offered makes it difficult for the user of the preparations to classify his individual specificity of the compatibility in order to take into account a possibly existing sensitivity to certain organics. In the end, this may mean that he prefers to refrain from using such products that appear critical to him.
Aus EP 0732 773 Al ist eine antibakteriell wirkende Zahnpasta bekannt, die ein Kalzium enthaltendes Phosphat beinhaltet, das ein antibakterielles Metall im metallischen Zustand trägt. Als antibakterielles Metall wird Silber, Kupfer, Zink vorgeschlagen. Der metallische Zustand des Metalls wird dadurch erreicht, dass das Phosphat mit einer entsprechenden wässrigen Metallsalzlösung behandelt wird und anschließend in einer thermischen Umwandlungsstufe bei mindestens 800 C die Reduktion des Metallsalzes auf dem Phosphat erfolgt. Die Methode liefert keine reproduzierbaren Ergebnisse bezüglich der antibakteriellen Wirksamkeit der erhaltenen Zahnpasta bedingt durch die schwer zu quantifizierende Verteilung und Konzentration des antibakteriell wirksamen Metalls auf dem Phosphat als auch bezüglich der erzielten Körnung von Phosphat und Metall. Außerdem muss im thermischen Prozess mit Verlusten an Metall gerechnet werden.EP 0732 773 A1 discloses an antibacterial toothpaste which contains a calcium-containing phosphate which carries an antibacterial metal in the metallic state. As antibacterial metal silver, copper, zinc is proposed. The metallic state of the metal is achieved by treating the phosphate with an appropriate aqueous metal salt solution and then reducing the metal salt on the phosphate in a thermal conversion step at at least 800 ° C. The method provides no reproducible results in terms of antibacterial efficacy of the resulting toothpaste due to the difficult to quantify distribution and concentration of the antibacterial metal on the phosphate as well as with respect to the obtained granulation of phosphate and metal. In addition, it must be expected in the thermal process with losses of metal.
Aus EP 0251 783 Bl/ DE 37 85 253 T2 ist eine antimikrobielle Zusammensetzung bekannt, die eine Silberverbindung beinhaltet, welche auf einem synthetischen, körnchenförmigen, physiologisch inerten Träger, der eine ausgedehnte Oberfläche aufweist, abgeschieden ist. Silberverbindungen haben den Nachteil, dass ionisches Silber in Gegenwart von Licht oder anderer Strahlung instabil ist. Diese Eigenschaft der Silberverbindungen lässt sich auch nicht absolut dadurch unterdrücken, dass die abgeschiedene Silberverbindung nur auf bestimmte, in wässriger Umgebung im wesentlichen unlösliche Trägerstoffe abgeschieden ist. Derartige Zusammensetzungen haben deshalb im allgemeinen eine unzureichende Lagerfähigkeit und damit eine nur zeitlich begrenzte antimikrobielle Wirksamkeit. Dieser Zeitraum ist jedoch schwerlich quantifizierbar, so dass der Anwender eines derartigen Produktes verunsichert darüber ist, inwieweit selbiges noch ausreichend aktiv ist.EP 0251 783 B1 / DE 37 85 253 T2 discloses an antimicrobial composition comprising a silver compound deposited on a synthetic, granular, physiologically inert support having an extended surface area. Silver compounds have the disadvantage that ionic silver is unstable in the presence of light or other radiation. Also, this property of the silver compounds can not be absolutely suppressed by depositing the deposited silver compound only on certain carriers which are substantially insoluble in an aqueous environment. Therefore, such compositions generally have inadequate shelf life and thus only limited antimicrobial efficacy. However, this period of time is difficult to quantify, so that the user of such a product is unsure about the extent to which the same is still sufficiently active.
Es ist auch bekannt, dass die oligodynamische Wirksamkeit von Silber umso höher wird, je feindisperser die Silberpartikel angesiedelt werden. So wird z.B. nanoskaliges Silber vermit - tels eines zubereiteten Vorproduktes in Kunststoffprodukte, wie Katheder, Schläuche etc., die für medizinische Zwecke Anwendung finden, eingebracht.It is also known that the more finely dispersed the silver particles, the higher the oligodynamic activity of silver becomes. For example, nanoscale silver by means of a prepared precursor in plastic products, such as catheters, tubes, etc., which are used for medical purposes, introduced.
Der Erfindung liegt die Aufgabe zu Grunde, ein antimikrobiell wirksames Präparat zur im wesentlichen humanen äußerlichen Anwendung für pharmazeutische und/oder kosmetische Zwecke zu entwickeln, welches nanoskaliges metallisches Silber enthält, das mit hoher Reproduzierbarkeit quantifizierbar ist und das eine stabile Lagerungsbeständigkeit aufweist. Die Aufgabe wird gelöst durch ein antimikrobiell wirksames Präparat unter Verwendung von nanoskaligem elementarem Silber, welches auf einem inerten Trägermaterial abgeschieden ist und das beschichtete Trägermaterial in Form eines Vorproduktes in das Präparat eingearbeitet ist, wobei das Präparat dadurch gekennzeichnet ist, dass es eine im wesentlichen pastöse Konsistenz aufweist und das Vorprodukt aus feinstteiligem Bariumsulfat und/oder äquivalenten inerten und medizinisch unbedenklichen anorganischen Verbindungen und/oder Mikrozellulose , auf welche das nanoskalige Silber abgeschieden ist, hergestellt ist. Vorzugsweise enthält das silberhaltige Vorprodukt Silber in einer Menge von 0,1 bis 50 Masse-% , im besonderen 3 bis 10 Masse-%, und ist in einer Menge von 0,2 bis 8o Masse-% im antimikrobiell wirksamen Präparat enthalten. Das Vorprodukt kann bei der ursprünglichen Zubereitung eines erfindungsgemäßen antimikrobiell wirksamen Präparates zugesetz werden. Das Vorprodukt ist aber auch jederzeit und einfach nachträglich in ein neutrales oder für pharmazeutische und/oder kosmetische Zwecke bereits geeignetes oder bereits mit anderweitig wirksamen Ingredienzien versetztes pastöses Präparat einbringbar, um ein erfindungsgemäßes antimikrobiell wirkendes Präparat zu erhalten. Es kann sich teilweise auch als vorteilhaft erweisen, das Vorprodukt durch Zusatz von in Wasser löslichen und/oder unlöslichen Silbersalzen zu aktivieren, um die oligodynamische Wirkung des nanoskaligen Silbers weiter zu erhöhen. Die antimikrobielle Wirksamkeit des Präparates ist durch gute Mischbarkeit aller Bestandteile präzise und leicht reproduzierbar einzustellen. Es hat sich gezeigt, dass alle angesetzten pastösen Präparate eine überraschend gute Lager - fähigkeit aufweisen, ohne ihre hohe antimikrobielle Wirksamkeit zu verlieren. Das erfindungsgemäße antimikrobiell wirksame pastöse Präparat ist in Form von Salben, Cremes, Gelen, Zahnpasten etc. vielfältig für pharmazeutische und kosmetische und humanmedizinische Zwecke einsetzbar und bringt überraschend schnelle Abkling- und Heileffekte bei Dermatosen, wie Akne vulgaris, Ekzemen, Neurodermitis, bei Brandverletzungen, Herpes, Pilzbefall, bei Fissuren, bei der Verhinderung und Behandlung von Wundinfektionen, Paradontitis u.a., und es ist problemlos und erfolgreich auch im HNO-, After- und Genitalbereich einsetzbar. Grundsätzlich ist auch die analoge Anwendung des erfindungsgemäßen antimikrobiell wirksamen Präparates in der Veterinärmedizin vorgesehen.The invention is based on the object of developing an antimicrobially active preparation for substantially human external application for pharmaceutical and / or cosmetic purposes, which contains nanoscale metallic silver which can be quantified with high reproducibility and which has a stable storage stability. The object is achieved by an antimicrobial active preparation using nanoscale elemental silver, which is deposited on an inert carrier material and the coated carrier material is incorporated in the form of an intermediate in the preparation, wherein the preparation is characterized in that it is a substantially pasty Having consistency and the precursor of feinstteiligem barium sulfate and / or equivalent inert and medically acceptable inorganic compounds and / or microcellulose on which the nanoscale silver is deposited, is prepared. Preferably, the silver-containing precursor contains silver in an amount of 0.1 to 50% by mass, especially 3 to 10% by mass, and is contained in an amount of 0.2 to 8% by mass in the antimicrobial preparation. The precursor can be added in the original preparation of an antimicrobial preparation according to the invention. However, the precursor can also be introduced at any time and simply subsequently in a neutral or for pharmaceutical and / or cosmetic purposes already suitable or already with otherwise effective ingredients added pasty preparation to obtain an inventive antimicrobial preparation. It may also prove advantageous in some cases to activate the precursor by adding water-soluble and / or insoluble silver salts in order to further increase the oligodynamic effect of the nanoscale silver. The antimicrobial efficacy of the preparation must be set precisely and easily reproducible thanks to the good miscibility of all components. It has been found that all prepared pasty preparations have a surprisingly good storage capacity without losing their high antimicrobial effectiveness. The antimicrobial pasty preparation according to the invention is widely used in the form of ointments, creams, gels, toothpastes etc. for pharmaceutical and cosmetic and human medical purposes and brings surprisingly fast decay and healing effects in dermatoses, such as acne vulgaris, eczema, eczema, burns, Herpes, fungal attack, fissures, in the prevention and treatment of wound infections, periodontitis, etc., and it is easily and successfully used in the ENT, anal and genital area. Basically, the analogous application of the antimicrobial preparation of the invention in veterinary medicine is provided.
Beispiel 1:Example 1:
2 bis 4g eines Vorproduktes, das aus einem mit 4 Masse-% Nanosilber beladenen mikrokristallinem Bariumsulfat bestand, wurden mit 3 ml dest. Wasser zu einer homogenen Paste angeteigt und im Verhältnis 1 : 20 mit einer hydrophilen Salbengrundlage und einem Anteil Vaselin weiß zu einer streichfähigen Salbe verrührt. Bei der Behandlung einer Akne vulgaris mit dieser Salbe war nach 3 Tagen eine komplette Abheilung zu verzeichnen.2 to 4 g of an intermediate, which consisted of a 4 wt% nanosilver-loaded microcrystalline barium sulfate, were distilled with 3 ml. Water into a homogeneous paste pasted and stirred in a ratio of 1:20 with a hydrophilic ointment base and a proportion of Vaseline white to a spreadable ointment. In the treatment of acne vulgaris with this ointment was complete after 3 days to record a complete.
Beispiel 2:Example 2:
Eine einfache käufliche Zahnpasta wurde mit einem Vorprodukt in Form einer mitA simple commercial toothpaste was made with a precursor in the form of a
10 Masse-% Nanosilber beschichtete Mikrozellulose in einer Menge von 10 Masse-% intensiv vermischt. Beide Zahnpasten, die das nanosilberhaltigen Vorprodukt enhaltende und die ursprüngliche, unpräparierte , wurden unter zahnärztlicher Kontrolle an Probanten begutachtet. Nach 14tägiger Anwendung trat mit der erfindungsgemäßen Zahnpaste eine drastische Verbesserung der Paradontitis ein, während mit der käuflichen Zahnpaste kein10 mass% nanosilver coated microcellulose in an amount of 10 mass% intensively mixed. Both toothpastes, containing the nanosilver-containing precursor and the original, unprepared, were evaluated under dental supervision on subjects. After 14 days of application occurred with the toothpaste according to the invention a drastic improvement of the periodontitis, while no commercial with the toothpaste
Effekt zu verzeichnen war. Effect was recorded.

Claims

Patentansprüche claims
1. Antimikrobiell wirkendes Präparat zur äußerlichen Anwendung für pharmazeutische und/oder kosmetische Zwecke unter Verwendung von nanoskaligem elementarem Silber, welches auf einem inerten Trägermaterial abgeschieden ist und das beschichtete Trägermaterial in Form eines Vorproduktes in das Präparat eingearbeitet ist, dadurch gekennzeichnet, dass das antimikrobiell wirkende Präparat vorzugsweise pastöse Konsistenz aufweist und das Vorprodukt aus feinstteiligem Bariumsulfat und/oder anderen inerten und medizinisch unbedenklichen anorganischen Verbindungen und/oder Mikrozellulose, aufweiche das nanoskalige elementare Silber abgeschieden ist, vorbereitet wird.1. antimicrobial preparation for external use for pharmaceutical and / or cosmetic purposes using nanoscale elemental silver, which is deposited on an inert carrier material and the coated carrier material is incorporated in the form of an intermediate in the preparation, characterized in that the antimicrobial acting Preparation preferably has a pasty consistency and the precursor of finely divided barium sulfate and / or other inert and medically acceptable inorganic compounds and / or microcellulose, on which the nanoscale elemental silver is deposited, is prepared.
2. Präparat nach Anspruch 1, dadurch gekennzeichnet, dass es Salben, Cremes, Gele, Zahnpasten etc. umfasst.2. A preparation according to claim 1, characterized in that it comprises ointments, creams, gels, toothpastes, etc.
3. Präparat nach Anspruch 1, dadurch gekennzeichnet, dass das Vorprodukt in einer Menge von 0,2 bis 80 Masse-% enthalten ist.3. A preparation according to claim 1, characterized in that the precursor is contained in an amount of 0.2 to 80% by mass.
4. Präparat nach Anspruch 1, dadurch gekennzeichnet, dass das Vorprodukt Silber in einer Menge von 0,1 bis 50 Masse-%, vorzugsweise 3 bis 10 Masse-% enthält.4. A preparation according to claim 1, characterized in that the precursor contains silver in an amount of 0.1 to 50% by mass, preferably 3 to 10% by mass.
5. Präparat nach Anspruch 1, dadurch gekennzeichnet, dass das Vorprodukt bei der ursprünglichen Herstellung des Präparates zugesetzt und/oder nachträglich eingebracht wurde.5. A preparation according to claim 1, characterized in that the precursor was added during the original preparation of the preparation and / or subsequently introduced.
6. Präparat nach Anspruch 1, dadurch gekennzeichnet, dass es als weitere Bestandteile die in pharmazeutischen und kosmetischen Präparaten üblichen Grund- und Hilfs- substanzen sowie anderweitig wirkenden Ingredienzien enthält.6. A preparation according to claim 1, characterized in that it contains as further constituents the usual in pharmaceutical and cosmetic preparations base and auxiliary substances as well as otherwise acting ingredients.
7. Präparat nach Anspruch 1, dadurch gekennzeichnet, dass das Vorprodukt durch in Wasser lösliche und/oder unlösliche Silbersalze aktiviert werden kann.7. A preparation according to claim 1, characterized in that the precursor can be activated by soluble in water and / or insoluble silver salts.
8. Präparat nach Anspruch 1 bis 7, dadurch gekennzeichnet, dass es bei Dermatosen, wie Akne vulgaris, Ekzemen, Brandverletzungen, Neurodermitis, Herpes, Pilzbefall etc., Fissuren, zur Verhinderung und Behandlung von Wundinfektionen, sowie im Mund- HNO-, After- und Genitalbereich eingesetzt wird. 8. A preparation according to claim 1 to 7, characterized in that it is used in dermatoses, such as acne vulgaris, eczema, burn injuries, atopic dermatitis, herpes, fungal infestation, etc., fissures, for the prevention and treatment of wound infections, as well as in the oral ENT, anus and genital area is used.
EP05715663A 2005-03-02 2005-03-02 Preparation with anti-microbial action for external use Withdrawn EP1853233A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/002192 WO2006092155A1 (en) 2005-03-02 2005-03-02 Preparation with anti-microbial action for external use

Publications (1)

Publication Number Publication Date
EP1853233A1 true EP1853233A1 (en) 2007-11-14

Family

ID=35285538

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05715663A Withdrawn EP1853233A1 (en) 2005-03-02 2005-03-02 Preparation with anti-microbial action for external use

Country Status (2)

Country Link
EP (1) EP1853233A1 (en)
WO (1) WO2006092155A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007019768A1 (en) * 2007-04-25 2008-11-13 Thüringisches Institut für Textil- und Kunststoff-Forschung e.V. A process for producing a high whiteness bioactive cellulosic fiber
EP2018867A1 (en) * 2007-07-26 2009-01-28 Spirig Pharma AG Method for manufacturing an antimicrobial cosmetic and/or pharmaceutical compound for topical application
ES2363397B1 (en) * 2010-01-18 2013-01-24 Sphieric Nanohealth, S.L. ANTISEPTIC MICROSPHERES.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19919770A1 (en) * 1999-04-30 2000-11-02 Henkel Kgaa Use of nanoscale antimicrobial agents in oral and / or dental care
ES2297196T3 (en) * 2002-09-10 2008-05-01 Prof. Dr. Josef-Peter Guggenbichler, Dr. Christoph Cichos Gbr Antimicrobial Argentum Technologies PROCEDURE TO PRODUCE AN ANTIMICROBIAL SYNTHETIC MATERIAL PRODUCT.
DE10342258A1 (en) * 2003-09-11 2005-04-07 Josef Peter Prof. Dr.med. Guggenbichler Antimicrobial composition for topical application for pharmaceutical or cosmetic purposes comprises elemental silver nanoparticles deposited on an inert support
DE10351611A1 (en) * 2003-11-05 2005-08-11 Guggenbichler, Josef-Peter, Prof.Dr. Liquid phase containing pure nano-particulate silver, useful in antimicrobial pharmaceutical or cosmetic preparations, obtained by eluting silver from (in)organic solid precursor with (in)organic liquid phase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006092155A1 *

Also Published As

Publication number Publication date
WO2006092155A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
DE3650734T2 (en) Pharmaceutical carriers to reduce transdermal flow
EP1269983B1 (en) Use of 1,2-Decanediol against germs which cause body malodour
EP1658040B1 (en) Silver-and zinc-containing product
DE60216634T2 (en) GEL WITH AT LEAST ONE RETINOID AND BENZOYL PEROXIDE
DE10340277B4 (en) Personal care products containing silver agglomerates
DE10342258A1 (en) Antimicrobial composition for topical application for pharmaceutical or cosmetic purposes comprises elemental silver nanoparticles deposited on an inert support
CH638981A5 (en) TOPICAL THERAPEUTIC AGENT FOR TREATING ACNE VULGARIS.
EP0060553A1 (en) Preparation for treating outer skin wounds and process for manufacturing said preparation
DE2933250A1 (en) COVER MATERIAL
DE2611725A1 (en) ZINC SULPHADIAZINE AND DERMATOTHERAPEUTIC AGENTS, CONTAINING IT, FOR THE TREATMENT OF BURNS
DE69619052T2 (en) Solid, anhydrous, pharmaceutical preparations for vaginal use
DE2900740C2 (en) Dermatologically effective cream
DE3302739A1 (en) OXIDATION STABLE MEDIUM
DE69025206T2 (en) USE OF AROMATIC BENZOATS AS DEODORANTS
CH645268A5 (en) BACTERIOSTATIC AND METHOD FOR THE PRODUCTION THEREOF.
EP2283802B1 (en) Medicinal preparation for treating inflammatory processes
EP1853233A1 (en) Preparation with anti-microbial action for external use
DE69924741T2 (en) USE OF A COMPOSITION FOR THE PRODUCTION OF A MEDICAMENT FOR PREVENTING AND TREATING PARODONTITIS
DE69105094T2 (en) Aqueous gel of retinoic acid and hydroxypropyl beta cyclodextrin.
WO2001007035A1 (en) Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues
DE1617306C3 (en) Dentifrices for preventing dental disease
DE69709317T2 (en) ANTISEPTIC COMPOSITIONS BASED ON CHLOROBUTANOL AND CHLORHEXIDINE
DE4125048A1 (en) Retard pharmaceutical prepn. for periodontitis treatment - contains anti-periodontitis drug esp. metronidazole, in cationic (meth)acrylic] polymer matrix pref. used as film strip
DE102012000416A1 (en) Topical composition, useful for treating wounds, preferably open wounds and ulcers, comprises fusafungine and/or one of its derivative and onion extract
DE112008001612B4 (en) Antimicrobial cosmetic and / or pharmaceutical compositions for topical use, process for their preparation and their use in the treatment of diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20070920

Extension state: HR

Payment date: 20070920

17Q First examination report despatched

Effective date: 20080724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101001